Expression of Protein S in the Murine Heart and Cultured Mouse Cardiomyocytes Is Down-regulated by Cytokines

Summary

Protein S (PS), a co-factor of activated protein C, is a vitamin K-dependent anticoagulant protein and is known to be produced extrahepatically. In the present study, the concentration of PS mRNA was determined tissue by tissue in the mouse, and it was high in lung, adrenal and heart as well as in liver. We further investigated the effects of lipopolysaccharide (LPS), tumor necrosis factor-α (TNF-α), and interleukin-1 (IL-1) on the PS mRNA expression in murine tissues in vivo. Although LPS and TNF-α significantly decreased the expression level of PS mRNA in all tissues examined (e.g., lung, liver, heart, and kidney) and the PS antigen level in plasma, the suppressive effect of IL-1 on PS gene expression was limited to heart. More specifically, considerable amounts of PS mRNA and antigen were expressed in a cultured mouse cardiomyocyte cell line, and again, treatment with IL-1 decreased the PS expression in these cells. These observations raise a possibility that the expression of cardiac PS may contribute to the regional anticoagulant potential in heart, and suggest that the decreased PS expression by cytokines may result in an increase in the systemic and/or regional prothrombotic potential under inflammatory conditions.

Keywords

Anticoagulant - interleukin-1 - tumor necrosis factor-α - cardiomyocyte - gene regulation

• References

• 1 Dahlback B. Protein S and C4b-binding protein: Components involved in the regulation of the protein C anticoagulant system. Thromb Haemost 1991; 66: 49-61.
• 2 Walker FJ. Regulation of activated protein C by protein S. The role of phospholipid in factor Va inactivation. J Biol Chem 1981; 256: 11128-31.
• 3 Kane WH, Davie EW. Blood coagulation factors V and VIII: structural and functional similarities and their relationship to hemorrhagic and thrombotic disorders. Blood 1988; 71: 539-55.
• 4 Mann KG, Jenny RJ, Krishnaswamy S. Cofactor proteins in the assembly and expression of blood clotting enzyme complexes. Ann Rev Biochem 1988; 57: 915-56.
• 5 Esmon CT. The protein C anticoagulant pathway. Arterioscler Thromb 1992; 12: 135-45.
• 6 Dahlback B. Purification of human C4b-binding protein and formation of its complex with vitamin K-dependent protein S. Biochem J 1983; 209: 847-56.
• 7 He X, Shen L, Bjartell A, Dahlback B. The gene encoding vitamin K-dependent anticoagulant protein S is expressed in multiple rabbit organs as demonstrated by Northern blotting, in situ hybridization, and immunohisto-chemistry. J Histochem Cytochem 1995; 43: 85-96.
• 8 Yamamoto K, Loskutoff DJ. Extrahepatic expression and regulation of protein C in the mouse. Am J Pathol 1998; 153: 547-55.
• 9 Comp PC, Esmon CT. Recurrent venous thromboembolism in patients with a partial deficiency of protein S. N Engl J Med 1984; 311: 1525-8.
• 10 Schwarz HP, Fischer M, Hopmeier P, Batard MA, Griffin JH. Plasma protein S deficiency in familial thrombotic disease. Blood 1984; 64: 1297-300.
• 11 Kamiya T, Sugihara T, Ogata K, Saito H, Suzuki K, Nishioka J, Hashimoto S, Yamagata K. Inherited deficiency of protein S in a Japanese family with recurrent venous thrombosis: a study of three generations. Blood 1986; 67: 406-10.
• 12 Ploos van Amstel HK, Huisman MV, Reitsma PH, ten Cate JW, Bertina RM. Partial protein S gene deletion in a family with hereditary thrombophilia. Blood 1989; 73: 479-83.
• 13 Schmidel DK, Nelson RM, Broxson EH, Comp PC, Marlar RA, Long GL. A 5.3-kb deletion including exon XIII of the protein Sgene occurs in two protein S-deficient families. Blood 1991; 77: 551-9.
• 14 Yamazaki T, Katsumi A, Kagami K, Okamoto Y, Sugiura I, Hamaguchi M, Kojima T, Takamatsu J, Saito H. Molecular basis of a hereditary type I protein S deficiency caused by a substitution of Cys for Arg474. Blood 1996; 87: 4643-50.
• 15 Okamoto Y, Yamazaki T, Katsumi A, Kojima T, Takamatsu J, Nishida M, Saito H. A novel nonsense mutation associated with an exon skipping in a patient with hereditary protein S deficiency type I. Thromb Haemost 1996; 75: 877-82.
• 16 Yamazaki T, Katsumi A, Okamoto Y, Takafuta T, Tsuzuki S, Kagami K, Sugiura I, Kojima T, Fujimura K, Saito H. Two distinct novel splice site mutations in a compound heterozygous patient with protein S deficiency. Thromb Haemost 1997; 77: 14-20.
• 17 Yamamoto K, Matsushita T, Sugiura I, Takamatsu J, Iwasaki E, Wada H, Deguchi K, Shirakawa S, Saito H. Homozygous protein C deficiency: identification of a novel missense mutation that causes impaired secretion of the mutant protein C. J Lab Clin Med 1992; 119: 682-9.
• 18 Yamamoto K, Tanimoto M, Emi N, Matsushita T, Takamatsu J, Saito H. Impaired secretion of the elongated mutant of protein C (protein C-Nagoya): molecular and cellular basis for hereditary protein C deficiency. J Clin Invest 1992; 90: 2439-46.
• 19 D’Angelo A, Vigano-D’Angelo S, Esmon CT, Comp PC. Acquired deficiencies of protein S: Protein S activity during oral anticoagulation, in liver disease and in disseminated intravascular coagulation. J Clin Invest 1988; 81: 1445-54.
• 20 Bertina RM, van Wijngaarden A, Reinalda-Poot J, Poort SR, Bom VJ. Determination of plasma protein S – the protein cofactor of activated protein C. Thromb Haemost 1985; 53: 268-72.
• 21 Comp PC, Thurnau GR, Welsh J, Esmon CT. Functional and immunologic protein S levels are decreased during pregnancy. Blood 1986; 68: 881-5.
• 22 Boerger LM, Morris PC, Thurnau GR, Esmon CT, Comp PC. Oral contraceptives and gender affect protein S status. Blood 1987; 69: 692-4.
• 23 Keeling DM, Campbell SJ, Mackie IJ, Machin SJ, Isenberg DA. Total and free protein S in systemic lupus erythematosus. Thromb Res 1990; 60: 237-40.
• 24 Bone RC. The pathogenesis of sepsis. Ann Intern Med 1991; 115: 457-69.
• 25 Beutler B, Cerami A. The biology of cachectin/TNF: A primary mediator of the host response. Ann Rev Immunol 1989; 7: 625-55.
• 26 Vassalli P. The pathophysiology of tumor necrosis factors. Ann Rev Immunol 1992; 10: 411-52.
• 27 Scarpati EM, Sadler JE. Regulation of endothelial cell coagulant properties: Modulation of tissue factor, plasminogen activator inhibitors and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor. J Biol Chem 1989; 264: 20705-13.
• 28 Schleef RR, Bevilacqua MP, Sawdey M, Gimbrone Jr MA, Loskutoff DJ. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type-1 plasminogen activator inhibitor. J Biol Chem 1988; 263: 5797-803.
• 29 Sawdey M, Podor TJ, Loskutoff DJ. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells: Induction by transforming growth factor-β, lipopolysaccharide, and tumor necrosis factor-α. J Biol Chem 1989; 264: 10396-401.
• 30 Yamamoto K, Loskutoff DJ. Fibrin deposition in tissues from endotoxin-treated mice correlates with decreases in the expression of urokinase-type but not tissue-type plasminogen activator. J Clin Invest 1996; 97: 2440-51.
• 31 Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU. Endotoxin enhances tissue factor and suppresses thrombomodulin expression of human vascular endothelium in vitro. J Clin Invest 1987; 79: 124-30.
• 32 Lentz SR, Tsiang M, Sadler JE. Regulation of thrombomodulin by tumor necrosis factor-α: Comparison of transcriptional and post-transcriptional mechanisms. Blood 1991; 77: 542-50.
• 33 Hooper WC, Phillips DJ, Ribeiro MJA, Benson JM, George VG, Ades EW, Evatt BL. Tumor necrosis factor-α down regulates protein S secretion in human microvascular and umbilical vein endothelial cells but not in the HepG-2 hepatoma cell line. Blood 1994; 84: 483-9.
• 34 Benzakour O, Kanthou C. The anticoagulant factor, protein S, is produced by cultured human vascular smooth muscle cells and its expression is up-regulated by thrombin. Blood 2000; 95: 2008-14.
• 35 Chu MD, Sun J, Bird P. Cloning and sequencing of a cDNA encoding the murine vitamin-K dependent protein. Biochem Biophys Acta 1994; 1217: 325-8.
• 36 Claycomb WC, Lanson Jr NA, Stallworth BS, Egeland DB. HL-1 cells: A cardiac muscle cell line that contracts and retains phenotypic characteristics of the adult cardiomyocyte. Proc Natl Acad Sci USA 1998; 95: 2979-84.
• 37 Fair DS, Marler RA, Levin EG. Human endothelial cells synthesize protein S. Blood 1986; 67: 1168-71.
• 38 Stern D, Brett J, Harris K, Nawroth P. Participation of endothelial cells in the protein C-protein S anticoagulant pathway: the synthesis and release of protein S. J Cell Biol 1986; 102: 1971-8.
• 39 Maillard C, Berruyer M, Serre CM, Dechavanne M, Delmas PD. Protein S a vitamin K-dependent protein, is a bone matrix component synthesized and secreted by osteoblasts. Endocrinology 1992; 130: 1599-604.
• 40 Schwarz HP, Heeb MJ, Wencel-Drake JD, Griffin JH. Identification and quantification of protein S in human platelets. Blood 1985; 66: 1452-5.
• 41 Malm J, He X, Bjartell A, Shen L, Abrahamsson P-A, Dahlback B. Vitamin K-dependent protein S in Leydig cells of human testis. Biochem J 1994; 302: 845-50.
• 42 Stitt TN, Conn G, Gore M, Lai C, Bruno J, Radziejewski C, Mattsson K, Fisher J, Gies DR, Jones PF, Masiakowski P, Ryan TE, Tobkes NJ, Chen DH, DiStefano PS, Long GL, Basilico C, Goldfarb MP, Lemke G, Glass DJ, Yancopoulos GD. The anticoagulation factor protein S and its relative, Gas6, are ligands for the Tyro3/Axl family of receptor tyrosine kinases. Cell 1995; 80: 661-70.
• 43 Jamison CS, Mcdowell SA, Marlar RA, Degen SJF. Developmental expression of protein C and protein S in the rat. Thromb Res 1995; 78: 407-19.
• 44 Griffin JH, Mosher DF, Zimmerman TS, Kleiss AJ. Protein C an anti-thrombotic protein, is reduced in hospitalized patients with intravascular coagulation. Blood 1982; 60: 261-4.
• 45 Marlar RA, Endres-Brooks J, Miller C. Serial studies of protein C and its plasma inhibitor in patients with disseminated intravascular coagulation. Blood 1985; 66: 59-63.
• 46 Fijnvandraat K, Derkx B, Peters M, Bijlmer R, Sturk A, Prins MH, van Deventer SJH, ten Cate JW. Coagulation activation and tissue necrosis in meningococcal septic shock: severely reduced protein C levels predict a high mortality. Thromb Haemost 1995; 73: 15-20.
• 47 Hesselvik JF, Malm J, Dahlback B, Blomback M. Protein C protein S and C4b-binding protein in severe infection and septic shock. Thromb Haemost 1991; 65: 126-9.
• 48 Yamamoto K, Shimokawa T, Kojima T, Loskutoff DJ, Saito H. Regulation of murine protein C gene expression in vivo: effects of tumor necrosis factor-α, interleukin-1, and transforming growth factor-β. Thromb Haemost 1999; 82: 1297-301.
• 49 Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J Exp Med 1986; 163: 740-5.
• 50 Sawdey MS, Loskutoff DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-α, and transforming growth-factor-β. J Clin Invest 1991; 88: 1346-53.
• 51 Dinarello CA. Interleukin-1 and interleukin-1 antagonism. Blood 1991; 77: 1627-52.
• 52 Bevilacqua MP, Schleef RR, Gimbrone Jr MA, Loskutoff DJ. Regulation of the fibrinolytic system of cultured vascular endothelium by interleukin 1. J Clin Invest 1986; 78: 587-91.
• 53 Jansen PM, Boermeester MA, Fischer E, de Jong IW, van der Poll T, Moldawer LL, Hack CE, Lowry SF. Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase A₂ insepsis: Studies in nonhuman primates after interleukin-1 administration and during lethal bacteremia. Blood 1995; 86: 1027-34.
• 54 Fischer E, Marano MA, Barber AE, Hudson A, Lee K, Rock CS, Hawes AS, Thompson RC, Hayes TJ, Anderson TD, Benjamin WR, Lowry SF, Moldawer LL. Comparison between effects of interleukin-1 administration and sublethal endotoxemia in primates. Am J Physiol 1991; 261: R442-52.